The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

As symptoms worsen ... We expect this approval will expand treatment options for adult patients with severe myasthenia gravis." “It is not necessary to be a genius to become a researcher.

Myasthenia gravis (MG) should be classified according to antibody status (acetylcholine, MuSK, LRP4, titin), thymus (hyperplasia, neoplasia, atrophy), age at debut (< or >50 years), symptom ...

UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...

Supplementary treatment with radiation and cytostatic ... No writing assistance was utilized in the production of this manuscript. Myasthenia gravis (MG) should be subgrouped into early-onset ...

It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.

New research at the University of Alberta may make it easier to diagnose serious diseases that disrupt the body's energy ...

The AURORA trial will involve approximately 100 participants and assess the efficacy of Descartes-08 compared to placebo, focusing on improvements in MG symptoms. Earlier Phase 2b results showed ...

Approval in Myasthenia gravis in key markets could eventually ... to suffer from significant unresolved disease symptoms despite existing treatment options," said John Orloff, M.D., executive ...